GDF15 and metabolic dysfunction-associated steatotic liver disease: Increased GDF15 levels were reported to participate in the pathogenesis of metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes, cardiovascular disease such as hypertrophy and atherosclerosis, and some type of cancers such as PCa, breast cancer and gastric cancer [25–27].